Clinical evaluation of venlafaxine
Clinical evaluation of venlafaxine
复制标题
DOI：
10.1097/00004714-199606002-00007
复制
发表时间：
1996-06-01
影响因子：
2.9
通讯作者：
Ballenger, JC
中科院分区：
文献类型：
--
作者：
Ballenger, JC
最近的研究表明，文拉法辛对于不同严重程度的抑郁症患者是一种有效的一线药物。回顾了两项评估文拉法辛疗效的代表性临床试验：一项是在重症住院患者中进行的，另一项是在门诊患者中进行的。对安慰剂对照试验中93名住院患者和主动对照试验中224名门诊患者的疗效进行了评分。在每个试验中，研究患者的人口统计学和基线评分相似。在两项试验中，文拉法辛明显比安慰剂更有效。对住院患者的研究表明，文拉法辛抗抑郁疗效的快速发作和焦虑共病症状的减少。在门诊患者的研究中，抗胆碱能副作用通常与三环类抗抑郁药（如丙咪嗪）相关，但未发现与文拉法辛相关，尽管会发生恶心。这些临床研究的结果证实了先前的研究结果，即文拉法辛是一种有效的一线药物，用于治疗住院患者和门诊患者的抑郁症。
Recent studies have shown venlafaxine to be an effective first-line agent for patients who have depression of varying severity. Two representative clinical trials to assess the efficacy of venlafaxine were reviewed: one in severely ill hospitalized patients and the other in outpatients. Efficacy was assessed using scores on several rating scales for 93 inpatients in the placebo-controlled trial and 224 outpatients in the active-control trial. Demographics and baseline scores were similar among study patients in each trial. In both trials, venlafaxine was significantly more effective than placebo. The study of inpatients demonstrated a rapid onset of antidepressant efficacy of venlafaxine and a reduction in comorbid symptoms of anxiety. In the study of outpatients, anticholinergic side effects commonly associated with tricyclic antidepressants such as imipramine were not found to be associated with venlafaxine, although some nausea occurred, Results of these clinical studies confirm those of previous studies that have shown venlafaxine to be an effective first-line agent for the management of depression in both hospitalized patients and outpatients.